Garren Hideki
Known title: Chief Medical OfficerCIK: 0001854126
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
COYA completes enrollment for Phase 2/3 ALS trial. Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.
Transaction History
| PRTA | ▲ Buy | Option Exercise | 2,000 | $50K | 9/13/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 2,000 | $111K | 9/13/2023 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 2,000 | $50K | 8/16/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 878 | $51K | 8/16/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 748 | $44K | 8/16/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 374 | $22K | 8/16/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 92 | $6K | 7/12/2023 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 2,000 | $50K | 7/12/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 1,908 | $129K | 7/12/2023 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 7,331 | $183K | 6/16/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 7,331 | $542K | 6/16/2023 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 4,669 | $116K | 6/14/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 509 | $37K | 6/14/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 971 | $71K | 6/14/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 2,534 | $189K | 6/14/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 655 | $49K | 6/14/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 6,000 | $292K | 3/15/2023 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 12,000 | $299K | 3/15/2023 | View on chart |
| PRTA | ▼ Sell | Open Market | 6,000 | $289K | 3/15/2023 | View on chart |
| COYA | ▲ Buy | Open Market | 2,000 | — | 1/3/2023 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 4,000 | $100K | 12/1/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 4,000 | $250K | 12/1/2022 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 4,000 | $100K | 11/1/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 3,489 | $216K | 11/1/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 511 | $32K | 11/1/2022 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 4,000 | $100K | 10/3/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 4,000 | $244K | 10/3/2022 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 4,000 | $100K | 9/15/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 4,000 | $120K | 9/15/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 4,000 | $122K | 8/1/2022 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 4,000 | $100K | 8/1/2022 | View on chart |
| PRTA | ▲ Buy | Option Exercise | 8,000 | $199K | 7/6/2022 | View on chart |
| PRTA | ▼ Sell | Open Market | 8,000 | $240K | 7/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prothena included in Alzheimer's Day stock watchlist
Prothena was featured in a Yahoo Finance article listing four Alzheimer's drug stocks to watch on World Alzheimer's Day. This inclusion highlights the company's relevance in the neurodegenerative disease sector. The stock is currently trading near its 52-week low, with technical indicators showing a rejection at support levels.
Prothena included in Alzheimer's Day stock watchlist. Prothena was featured in a Yahoo Finance article listing four Alzheimer's drug stocks to watch on World Alzheimer's Day. This inclusion highlights the company's relevance in the neurodegenerative disease sector. The stock is currently trading near its 52-week low, with technical indicators showing a rejection at support levels.